Parkinson's Disease and Stem Cell-Based Therapies: Current Research and Future Directions

References

[1] ---. “Stem Cell Therapy, the Market, the Opportunities and the Threat.”

[2] PubMed, vol. 12, no. 3, Jan. 2023, pp. 310–19.

[3] Biomedicine & Pharmacotherapy, vol. 137, Jan. 2021, p. 111236. https://doi.org/10.1016/j.biopha.2021.111236. Guo, Xiaoqian, et al. “Current Developments in Cell Replacement Therapy for Parkinson’s Disease.”

[4] Neuroscience, vol. 463, Mar. 2021, pp. 370–82. https://doi.org/10.1016/j.neuroscience.2021.03.022.Ghasroldasht, Mohammad Mousaei, et al. “Stem Cell Therapy: From Idea to Clinical Practice.”

[5] International Journal of Molecular Sciences, vol. 23, no. 5, Mar. 2022, p. 2850. https://doi.org/10.3390/ijms23052850.Moy, Alan, et al. “The Challenges to Advancing Induced Pluripotent Stem Cell-Dependent Cell Replacement Therapy.”

[6] Medical Research Archives, vol. 11, no. 11, Jan. 2023, https://doi.org/10.18103/mra.v11i11.4784.Nagpal, Anjali, et al.

[7] Value in Health, vol. 22, no. 2, Aug. 2018, pp. 254–62. https://doi.org/10.1016/j.jval.2018.07.878.Wijeyekoon, Ruwani, and Roger A. Barker. “Cell Replacement Therapy for Parkinson’s Disease.”

[8] Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1792, no. 7, Oct. 2008, pp. 688–702. https://doi.org/10.1016/j.bbadis.2008.10.007.Xiao, Bin, et al. “Induced Pluripotent Stem Cells in Parkinson’s Disease: Scientific and Clinical Challenges.”

[9] Journal of Neurology Neurosurgery & Psychiatry, vol. 87, no. 7, Feb. 2016, pp. 697–702. https://doi.org/10.1136/jnnp-2015-312036.Yefroyev, David A., and Sha Jin. “Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases.”

[10] Biomedicines, vol. 10, no. 2, Jan. 2022, p. 208. https://doi.org/10.3390/biomedicines10020208.Young, Henry E. “Treating Parkinson Disease With Adult Stem Cells.”

[11] Journal of Neurological Disorders, vol. 01, no. 02, Jan. 2013, https://doi.org/10.4172/2329-6895.1000121.Zeng, Xinlin, and Hua Qin. “Stem Cell Transplantation for Parkinson’s Disease: Current Challenges and Perspectives.”

[12] Aging and Disease, vol. 13, no. 6, Jan. 2022, p. 1652. https://doi.org/10.14336/ad.2022.0312.Qarin, Shamma, et al. “The Immunogenicity of Midbrain Dopaminergic Neurons and the Implications for Neural Grafting Trials in Parkinson’s Disease.”

[13] Neuronal Signaling, vol. 5, no. 3, Aug. 2021, https://doi.org/10.1042/ns20200083.Oz, Tuba, et al. “Neural Stem Cells for Parkinson’s Disease Management: Challenges, Nanobased Support, and Prospects.”

[14] World Journal of Stem Cells, vol. 15, no. 7, July 2023, pp. 687– 700. https://doi.org/10.4252/wjsc.v15.i7.687.Umer, A., Ghouri, M. D., Muyizere, T., Aqib, R. M., Muhaymin, A., Cai, R., & Chen, C. (2023). Engineered Nano−Bio interfaces for stem cell therapy. In

[15] Precis. Chem. (pp. 341–356).

[16] Nature Communications, vol. 12, no. 1, May 2021, https://doi.org/10.1038/s41467-021-23125-9.Parish, Clare L., and Lachlan H. Thompson. “Embryonic Stem Cells Go From Bench to Bedside for Parkinson’s Disease.”

[17] Stem Cell Research & Therapy, vol. 13, no. 1, July 2022, https://doi.org/10.1186/s13287-022-03050-4.Cohen-Adad, Julien, and Claudia Wheeler-Kingshott.

[18] Quantitative MRI of the Spinal Cord. Academic Press, 2014.Pinjala, Poojitha, et al. “CRISPR/Cas9 Assisted Stem Cell Therapy in Parkinson’s Disease.”

[19] Biomaterials Research, vol. 27, no. 1, Feb. 2023, https://doi.org/10.1186/s40824-023-00381-y.Hoang, Duc M., et al.

[20] Signal Transduction and Targeted Therapy, vol. 7, no. 1, Aug. 2022, https://doi.org/10.1038/s41392-022-01134-4.Hoang, D.M., Pham, P.T., Bach, T.Q.

[21] et al. Stem cell-based therapy for human diseases. Sig Transduct Target Ther 7, 272 (2022). https://doi.org/10.1038/s41392022-01134-4Margiana, R., Markov, A., Zekiy, A.O.

[22] et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther 13, 366 (2022). https://doi.org/10.1186/s13287-022-03054-0 Pathak, Surajit, and Antara Banerjee.

[23] Cancer Stem Cells: New Horizons in Cancer Therapies. Springer Nature, 2020.Aly, Riham Mohamed. “Current state of stem cell-based therapies: an overview.”

[24] Stem cell investigation vol. 7 8. 15 May. 2020, doi:10.21037/sci2020-001Xiao, Zhuangzhuang, et al. “The Potential Therapy With Dental Tissue-derived Mesenchymal Stem Cells in Parkinson’s Disease.”

[25] Stem Cell Research & Therapy, vol. 12, no. 1, Jan. 2021, https://doi.org/10.1186/s13287-020-01957-4.Zare, Sona, et al. “Types of Stem Cells in Regenerative Medicine: A Review.”

[26] Journal of Skin and Stem Cell, vol. 1, no. 3, Dec. 2014, https://doi.org/10.17795/jssc28471.. Zakrzewski, Wojciech, et al.

[27] Stem Cell Research & Therapy, vol. 10, no. 1, Feb. 2019, https://doi.org/10.1186/s13287-019-1165-5. Larijani, Bagher et al. “Stem cell therapy in treatment of different diseases.” Acta medica Iranica vol. 50,2 (2012): 79-96.

[28] Kim, Seung U., et al. “Neural Stem Cell‐based Treatment for Neurodegenerative Diseases.”

[29] Neuropathology, vol. 33, no. 5, Feb. 2013, pp. 491–504.

[30] American Journal of Phytomedicine and Clinical Therapeutics, vol. 2, no. 7, July 2014, pp. 919–30. ---. “Clinical Application of Mesenchymal Stem Cell in Regenerative Medicine: A Narrative Review.”

[31] Stem Cell Research & Therapy, vol. 13, no. 1, July 2022, https://doi.org/10.1186/s13287-022-03054-0.. ---. “Role of Human Mesenchymal Stem Cells in Regenerative Therapy.” Cells, vol. 10, no. 1, Dec. 2020, p. 54.

[32] https://doi.org/10.3390/cells10010054. . Tian, Zeyu, et al.

[33] Progress in Molecular Biology and Translational Science, Jan. 2023, pp. 3–32. https://doi.org/10.1016/bs.pmbts.2023.02.012. Kolios, George, and Yuben Moodley. “Introduction to Stem Cells and Regenerative Medicine.”

[34] Respiration, vol. 85, no. 1, Dec. 2012, pp. 3–10. https://doi.org/10.1159/000345615.. Anjum, Anam et al. “Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms.” International journal of molecular sciences vol. 21,20 7533. 13 Oct. 2020, doi:10.3390/ijms21207533 17.

[35] Edgar, L., et al. “Regenerative Medicine, Organ Bioengineering and Transplantation.”

[36] British Journal of Surgery, vol. 107, no. 7, May 2020, pp. 793– 800. https://doi.org/10.1002/bjs.11686. Yamada, Satsuki et al. “Regenerative medicine clinical readiness.” Regenerative medicine vol. 16,3 (2021): 309-322. doi:10.2217/rme-2020- 0178 19.

[37] ---. “Introduction to Stem Cells and Regenerative Medicine.” 39.Respiration, vol. 85, no. 1, Dec. 2012, pp. 3–10. https://doi.org/10.1159/000345615.---. “Evolving Trends in Stem Cell

[38] International Journal of Surgery, vol. 110, no. 11, July 2024, pp. 6862–68. https://doi.org/10.1097/js9.0000000000001948.---. “Stem Cell Therapy, the Market, the Opportunities and the Threat.”

[39] PubMed, vol. 12, no. 3, Jan. 2023, pp. 310–19.

[40] Nano Letters, vol. 10, no. 9, Aug. 2010, pp. 3223–30. https://doi.org/10.1021/nl102184c.---. “Key Challenges in Bringing CRISPR-mediated Somatic Cell Therapy Into the Clinic.”

[41] Genome Medicine, vol. 9, no. 1, Sept. 2017, https://doi.org/10.1186/s13073-017-0475-4.---. “The Immunogenicity of Midbrain Dopaminergic Neurons and the Implications for Neural

[42] Grafting Trials in Parkinson’s Disease.” Neuronal Signaling, vol. 5, no. 3, Aug. 2021, https://doi.org/10.1042/ns20200083.

@article{1714220,
      author = {Darshana Padmakumar},
      title = {Parkinson's Disease and Stem Cell-Based  Therapies: Current Research and Future  Directions},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {8},
      pages = {495-500},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1714220.pdf},
      abstract = {Parkinson’s disease is a neurodegenerative disorder arising in elderly people above the age of 60. More than 10 million people worldwide are living with Parkinson’s disease.  The loss of dopaminergic neurons which produce and release dopamine leads to PD. These neurons play a crucial role in motor control and coordination. Current treatments include dopamine replacement therapy(DRT) which do not possess the potential in managing extreme motor symptoms in patients who have advanced PD. However, in recent years stem cell-based therapies have been studied due to their potential in treating PD. Cell replacement therapy(CRT) has emerged as a promising research area in which dopaminergic neurons are replaced with healthy neurons that seek to achieve sustained motor function improvements. Researchers have studied different types of stem cells, including embryonic stem cells (ESCs),neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (IPSCs).However, cell-based therapies still face various challenges such as tumorigenicity and ethical concerns for stem cells such as ESCs.However these challenges could be overcomed . For example, integrating nanotechnology and sttem cell based therapy could improve safety and efficasy of CRT. This review provides a comprehensive overview on the current treatments for Parkinson’s disease using stem cells , the challenges and the future directions for this path of research such as nano-stem treatments.},
      month = {February},
      doi = {https://doi.org/10.64388/IREV9I8-1714220}
  }